Benign Prostatic Hyperplasia: Diagnosis and Treatment Guideline

  title={Benign Prostatic Hyperplasia: Diagnosis and Treatment Guideline},
  author={M Lee and Roohollah Sharifi},
  journal={Annals of Pharmacotherapy},
  pages={481 - 486}
Objective To critique the US Department of Health and Human Services Public Health Service, Agency for Health Care Policy and Research, Clinical Practice Guideline on Benign Prostatic Hyperplasia: Diagnosis and Treatment; and to provide an update on management and treatment of benign prostatic hyperplasia (BPH) since the Guideline was published. Data Sources A review of the published medical literature in MEDLINE from 1994 to April 1996, limited in focus to drug treatment of BPH, English… Expand
10 Citations
Who Should Be Treated and How? Evidence-Based Medicine in Symptomatic BPH
Medical therapy with either finasteride or α1-blockers remains an attractive therapeutic alternative: both approaches are effective, reasonably well tolerated and in the ‘shorter’ term more cost-efficient than TURP. Expand
Hypertension in the elderly with coexisting benign prostatic hyperplasia.
To manage patients with hypertension and prostatism, hydrochlorothiazide 6.25 to 12.5 mg/day and tamsulosin 0.4 mg/ day would be an adequate combination, and a low dose of a long-acting calcium-entry blocker, a central alpha-agonist, an angiotensin-converting enzyme inhibitor, or an ang Elliotensin II receptor blocker should be considered. Expand
Combined low-frequency ultrasound and microbubble contrast agent for the treatment of benign prostatic hyperplasia.
It is suggested that lower frequency ultrasound may have a better effect on benign prostatic hyperplasia, and microbubble contrast agent application further strengthens this biological effect. Expand
Discovery and therapeutic promise of selective androgen receptor modulators.
The recent discovery of nonsteroidal selective androgens receptor modulators (SARMs) provides a promising alternative for testosterone replacement therapies with advantages including oral bioavailability, flexibility of structural modification, androgen receptor specificity, tissue selectivity, and the lack of steroid-related side effects. Expand
Análisis coste-efectividad del tratamiento de la hiperplasia prostática benigna de grado moderado
Objetivos Determinar la alternativa mas coste-efectiva del tratamiento de la hiperplasia prostatica benigna de grado moderado (HPB-GM) y conocer si las conclusiones pueden modificarse al variar elExpand
Nitro-Group-Containing Drugs.
The current Perspective covers various aspects of agents that contain nitro groups, their bioreductive activation mechanisms, their toxicities, and approaches to combat their toxicity issues. Expand
Citalopram for impulsive aggression.


Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis.
This combined analysis suggests that terazosin can be safely administered to both normotensive and hypertensive patients with symptomatic BPH. Expand
A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate.
For men with moderate symptoms of benign prostatic hyperplasia, surgery is more effective than watchful waiting in reducing the rate of treatment failure and improving genitourinary symptoms. Expand
A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.
This study unequivocally demonstrates the safety and efficacy of terazosin for the treatment of symptomatic BPH, and selective alpha 1-blockade is likely to gain widespread acceptance for the Treatment of BPH due to itssafety and efficacy. Expand
Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia*
This study suggests that terazosin is well tolerated and effective in long-term treatment of patients with BPH, with peak urinary flow rates significantly higher than baseline values. Expand
Benign prostatic hyperplasia. Hormonal treatment.
  • J. Mcconnell
  • Medicine
  • The Urologic clinics of North America
  • 1995
Of the available hormonal therapeutic agents, only finasteride appears to have an acceptable risk-benefit ratio and other 5 alpha-reductase inhibitors in the "pipeline," such as episteride, may have similar benefits. Expand
Flutamide in treatment of benign prostatic hypertrophy.
Flutamide may be a safe and effective drug for the treatment of symptomatic BPH and significant symptomatic improvements were noted in both groups. Expand
Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia.
The excellent safety profile and sustained clinical efficacy, over thirty-six months, of daily treatment withfinasteride 5 mg recommend finasteride as a low-risk medical option for the treatment of symptomatic benign prostatic hyperplasia. Expand
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24–30 month survey
Data demonstrate the usefulness of long-term treatment with alfuzosin in patients with uncomplicated, moderate BPH, and symptomatic assessment and urodynamic parameters remained stable, indicating the sustained effectiveness of therapy. Expand
Therapeutic controversies: clinical treatment of benign prostatic hyperplasia.
The growth of the prostate gland with development of a periurethral adenoma, which compresses the urethra, resulting in obstruction to flow of urine from the bladder, may interfere with emptying of the bladder. Expand
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
In men with benign prostatic hyperplasia, terazosin was effective therapy, whereas finasteride was not, and the combination of terazOSin and finasterside was no more effective than terazoshin alone. Expand